Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Dissociative or wake-promoting agent & onset: Within hours of first administration

Use the filters below to narrow your results.

generic:
None (1)
brand:
Spravato (1)
classes: (Click arrow to add another value)
mechanism:
None (1)
uses:
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
28 mg/device (each dose uses 2 devices) (1)
fda max:
84 mg per session (1)
routes:
Intranasal (under direct medical supervision) (1)
onset: (Click arrow to add another value)
duration:
Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)
halflife:
~7-12 hours (1)
bioavailability:
~48% intranasal (1)
pregnancy:
Avoid; may cause fetal harm (1)
legal:
Rx, Schedule III (US). REMS program required. (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"